中国实验血液学杂志最新文献

{"title":"[Expression and Clinical Significance of CaMKIIγ in Patients with Acute Myeloid Leukemia].","authors":"Ming-Kai Liu, Xu Dai, Xiao-Ying Zhao, Wei-Wei Zheng, Ya-Jing Ma","doi":"10.19746/j.cnki.issn.1009-2137.2025.03.015","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.03.015","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the expression and potential mechanism of calcium/calmodulin-dependent protein kinase II gamma (CaMKIIγ) in patients with acute myeloid leukemia (AML).</p><p><strong>Methods: </strong>Peripheral blood samples were collected from 90 AML patients, and mononuclear cells were isolated. The expression of CaMKIIγ was measured using real-time quantitative PCR and Western blot. The diagnostic value of CaMKIIγ for AML was assessed, and its correlation with clinical characteristics was analyzed using the clinical data of patients. Additionally, the molecular mechanisms of CaMKIIγ were preliminarily explored.</p><p><strong>Results: </strong>Compared with the control group, the expression of <i>CaMKIIγ</i> was significantly upregulated in AML patients. Receiver operating characteristic (ROC) curve analysis showed that <i>CaMKIIγ</i> could serve as a promising biomarker for distinguishing AML patients from healthy individuals. Furthermore, <i>CaMKIIγ</i> was significantly correlated with white blood cell (WBC) count and <i>FLT3-ITD</i> mutation. CaMKIIγ was highly expressed in both newly diagnosed and relapsed AML patients, while decreased during remission. In AML cell lines, the expression levels of CaMKIIγ were all elevated. Inhibition of phosphorylated CaMKIIγ by berbamine led to a decrease in pAKT and pSTAT5 expression.</p><p><strong>Conclusion: </strong>CaMKIIγ is significantly upregulated in AML patients, and is associated with poor clinicopathological features and unfavorable prognosis. It may serve as a prognostic marker and potential therapeutic target in AML. Its expression may be related to the activation of pAKT and pSTAT5, suggesting that CaMKIIγ may contribute to the development and progression of AML through the activation of the AKT/STAT5 signaling pathway.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 3","pages":"726-732"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The Efficacy of Combination of Avatrombopag and rhIL-11 in Adult Patients of Acute Myeloid Leukemia with Cancer Treatment-Induced Thrombocytopenia].","authors":"Min-Na Luo, Hai-Tao Zhang, Si-Jie Zhao, Jing Li, Wen-Juan Wang, Peng-Cheng He","doi":"10.19746/j.cnki.issn.1009-2137.2025.03.033","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.03.033","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the safety and efficacy of avatrombopag（AVA） combined with rhIL-11 in treating thrombocytopenia induced by chemotherapy in acute myeloid leukemia.</p><p><strong>Methods: </strong>The clinical information of 8 patients in the real world who received avatrombopag combined with rhIL-11 in cancer treatment-induced thrombocytopenia(CTIT) after AML chemotherapy were retrospectively analyzed, and at the same time, 8 patients who received rhIL-11 only in CTIT after AML chemotherapy served as the control group, A preliminary observation was to summarize and compare the therapeutic efficacy and adverse effects between the two groups.</p><p><strong>Results: </strong>D3 and D7 platelet counts were not significantly different between the observation group and the control group after treatment. The platelet counts in the observation group was significantly higher than those of the control group on the 10th day after treatment (<i>P</i> < 0.01). The adverse reactions, such as weakness, abdominal pain, fatigue, nausea and edema after treatment were mild in the observation group and the control group. Except for one patient in the observation group who had a history of cerebral infarction before the onset of the disease and was routinely taking antiplatelet drugs, no thrombosis events occurred in the patients in the observation and control groups during the period of administration of the drug, and the total incidence rate of adverse reactions was not significantly different between the two groups.</p><p><strong>Conclusion: </strong>The combination of AVA and rhIL-11 can enhance platelet recovery in CTIT of AML patients after chemotherapy. Compared with the rhIL-11 alone group, the platelet recovery time in AVA+rhIL-11 group was significantly shorter, the platelet count on the 10th day after drug administration was significantly higher. No statistically significant difference in the total incidence rate of adverse reactions was observed between rhIL-11 alone group and AVA+rhIL-11 group.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 3","pages":"848-852"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical and Laboratory Characteristics of Acute Myeloid Leukemia, Myelodysplasia-Related].","authors":"Wei-Bin Li, Lan Yang, Shao-Jie Cheng, Ya Chen, Yan Jiang","doi":"10.19746/j.cnki.issn.1009-2137.2025.03.007","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.03.007","url":null,"abstract":"<p><strong>Objective: </strong>To understand clinical and laboratory characteristics of acute myeloid leukemia, myelodysplasia-related (AML-MR).</p><p><strong>Methods: </strong>Blood sample of one patient with AML-MR admitted to our hospital in September 2021 was collected and synthetically analyzed by using techniques including complete blood cell count, peripheral blood and bone marrow cell morphology, bone marrow pathology and immunohistochemistry, hematology examination, flow cytometry (FCM), chromosome karyotype analysis and molecular pathology. The clinical and laboratory characteristics of AML-MR were analyzed and summarized according to the World Health Organization (WHO) standards.</p><p><strong>Results: </strong>The patient showed pancytopenia and increased proportion of blasts in smear of peripheral blood cells. Bone marrow cytology and pathological examination showed significant proliferation of hematopoietic cells. Pathological immunohistochemistry showed increased expression of CD61, CD34, and CD117, while MPO, CD13, and CD33 were positive. FCM showed that abnormal myeloid progenitor cells accounted for approximately 18.61% of the total number of nuclear cells, with expression of CD34, CD13, CD117, HLA-DR, and CD33 (small amount). Additionally, 36.34% of the cells were primitive/immature red blood cells which expressed CD36, CD71, and CD117 (small amount). Chromosome karyotype analysis and molecular pathology detected three kinds of abnormalities including -5 and two kinds of <i>TP53</i> related gene mutation, respectively.</p><p><strong>Conclusion: </strong>AML-MR patient shows pancytopenia and increased proportion of blasts in smear of peripheral blood cells. Bone marrow cytology and pathological examination show significant proliferation of hematopoietic cells. FCM can detect myeloid progenitor cells and primitive/immature red blood cells, while chromosome karyotype analysis can detect three abnormal karyotypes.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 3","pages":"666-671"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Expression and Prognostic Significance of <i>MYCN</i> in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia].","authors":"Yue Liu, Yang Cao, Hui-Juan Chen, Jia-Yu Liu, Ying-Jie Miao, Wei-Ying Gu","doi":"10.19746/j.cnki.issn.1009-2137.2025.03.016","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.03.016","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to determine the expression levels and prognostic significance of <i>MYCN</i> in bone marrow of adult patients with newly diagnosed acute myeloid leukemia (AML).</p><p><strong>Methods: </strong>A total of 62 newly diagnosed patients with non-M3 AML were enrolled as the study group, and 20 healthy donors as the control group. Real-time quantitative reverse transcription-polymerase chain reaction (PCR) was performed to detect the expression level of <i>MYCN</i>, and the relationship between <i>MYCN</i> expression and prognosis of AML patients was analyzed.</p><p><strong>Results: </strong><i>MYCN</i> was up-regulated in newly diagnosed AML patients compared with normal controls (<i>P</i> < 0.001). Receiver operating characteristic (ROC) curve analysis revealed that <i>MYCN</i> could serve as a diagnostic biomarker for AML. Kaplan-Meier survival analysis showed that the patients with high <i>MYCN</i> expression had a shorter overall survival (OS) time than the patients with low <i>MYCN</i> expression (<i>P</i> =0.016). The expression level of <i>MYCN</i> was lower during the complete ressimion (CR) phase of AML compared to the initial diagnosis, but it returned to the initial diagnostic level or even higher during relapse phase. Multivariate Cox regression analysis showed that high expression of <i>MYCN</i> was an independent risk factor for OS of AML patients (<i>P</i> =0.021).</p><p><strong>Conclusion: </strong><i>MYCN</i> is highly expressed and associated with poor prognosis in de novo AML, which might be serve as a novel diagnostic and prognostic biomarker for adult AML.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 3","pages":"733-737"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The Effect of p.Thr241Asn and p.Cys389Gly Mutations on Coagulation Factor VII Structure and Function].","authors":"Li Zhou, Pu-Hui Zhou","doi":"10.19746/j.cnki.issn.1009-2137.2025.03.034","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.03.034","url":null,"abstract":"<p><strong>Objective: </strong>To identify <i>F7</i> gene mutations in one pedigree with congenital coagulation factor VII (FVII) deficiency and explore the effect of <i>F7</i> gene mutations on the structure and function of FVII.</p><p><strong>Methods: </strong>Prothrombin time (PT) and activated partial thromboplastin time (APTT) were measured based on the one-stage assay, and PT-based one stage assay was used to detect the activity of FII, V, VII and X. Genomic DNA was extracted from the peripheral blood of family members. The sequences of all the exons and exon-intron boundaries of <i>F7</i> were amplified by polymerase chain reaction (PCR) using specific primers followed by Sanger sequencing. PolyPhen-2, PROVEAN and Swiss-Pdb Viewer software were used to analyze the effect of mutations on the structure and function of FVII.</p><p><strong>Results: </strong>The proband had a prolonged PT (33.8 s) due to low FVII activity (6.6%) and normal APTT, and had a history of epistaxis. The proband's mother and father displayed a slightly prolonged PT (13.2 and 13.9 s, respectively), and their FVII activity was 40.3% and 38.3%, respectively. The compound heterozygous c.722C>A (p.Thr241Asn) in exon 7 and c.1165T>G (p.Cys389Gly) in exon 8 of <i>F7</i> gene were identified in the proband, and inherited from his father and mother, respectively. The p.Thr241Asn and p.Cys389Gly missense change were likely to have a damaging effect predicted by polyphen-2 and PROVEAN software. In silico modeling analysis showed that there was one hydrogen bond formed between wild-type Thr241 and Val249, two hydrogen bonds formed between mutant Asn241 and Val249 and between mutant Asn241 and Leu242, as well as one hydrogen bond and one disulfide bond formed between wild-type Cys389 and Leu370 and between wild-type Cys389 and Cys375, respectively. The hydrogen bond formed between mutant Gly389 and Leu370 and disulfide bond formed between mutant Gly389 and Cys375 both broke.</p><p><strong>Conclusions: </strong>FVII deficiency in this family is caused by p.Thr241Asn and p.Cys389Gly mutation. In silico modeling may be a valuable tool for understanding amino acid residues from variants leading to congenital FVII deficiency.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 3","pages":"853-857"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical Characteristics and Prognostic Analysis of Newly Diagnosed Acute Myeloid Leukemia Patients with <i>NRAS</i> and <i>KRAS</i> Gene Mutations].","authors":"Zhang-Yu Yu, Bo Cai, Yi Wang, Yang-Yang Lei, Bing-Xia Li, Yu-Fang Li, Yan-Ping Shi, Jia-Xin Chen, Shu-Hong Liu, Chang-Lin Yu, Mei Guo","doi":"10.19746/j.cnki.issn.1009-2137.2025.03.009","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.03.009","url":null,"abstract":"<p><strong>Objective: </strong>To retrospectively analyze the clinical characteristics, co-mutated genes in newly diagnosed acute myeloid leukemia (AML) patients with <i>NRAS</i> and <i>KRAS</i> gene mutations, and the impact of <i>NRAS</i> and <i>KRAS</i> mutations on prognosis.</p><p><strong>Methods: </strong>The clinical data and next-generation sequencing results of 80 newly diagnosed AML patients treated at our hospital from December 2018 to December 2023 were collected. The clinical characteristics, co-mutated genes of <i>NRAS</i> and <i>KRAS</i> , and the impact of <i>NRAS</i> and <i>KRAS</i> mutations on prognosis in newly diagnosed AML patients were analyzed.</p><p><strong>Results: </strong>Among 80 newly diagnosed AML patients, <i>NRAS</i> mutations were detected in 20 cases(25.0%), and <i>KRAS</i> mutations were detected in 9 cases(11.3%). <i>NRAS</i> mutations predominantly occurred at codons 12 and 13 of exon 2, as well as codon 61 of exon 3, while <i>KRAS</i> mutations were most commonly occurred at codons 12 and 13 of exon 2, all of which were missense mutations. There were no statistically significant differences observed in terms of age, sex, white blood cell count(WBC), hemoglobin(Hb), platelet count(PLT), bone marrow blasts, first induction chemotherapy regimen, CR1/CRi1 rates, chromosome karyotype, 2022 ELN risk classification and allogeneic hematopoietic stem cell transplantation(allo-HSCT) among the <i>NRAS</i> mutation group, <i>KRAS</i> mutation group and <i>NRAS</i>/<i>KRAS</i> wild-type group (<i>P</i> >0.05). <i>KRAS</i> mutations were significantly correlated with <i>PTPN11</i> mutations (<i>r</i> =0.344), whereas no genes significantly associated with <i>NRAS</i> mutations were found. Survival analysis showed that compared to the <i>NRAS</i>/<i>KRAS</i> wild-type group, patients with <i>NRAS</i> mutation had a relatively higher 5-year overall survival (OS) rate and relapse-free survival (RFS) rate, though the differences were not statistically significant (<i>P</i> =0.097, <i>P</i> =0.249). Compared to the <i>NRAS</i>/<i>KRAS</i> wild-type group, patients with <i>KRAS</i> mutation had a lower 5-year OS rate and RFS rate, with no significant differences observed (<i>P</i> =0.275, <i>P</i> =0.442). There was no significant difference in the 5-year RFS rate between the <i>KRAS</i> mutation group and <i>NRAS</i> mutation group (<i>P</i> =0.157), but the 5-year OS rate of patients with <i>KRAS</i> mutation was significantly lower than that of patients with <i>NRAS</i> mutation (<i>P</i> =0.037).</p><p><strong>Conclusion: </strong>In newly diagnosed AML patients, <i>KRAS</i> mutation was significantly correlated with <i>PTPN11</i> mutation. Compared to patients with <i>NRAS</i>/<i>KRAS</i> wild-type, those with <i>NRAS</i> mutation showed a more favorable prognosis, while patients with <i>KRAS</i> mutation showed a poorer prognosis; however, these differences did not reach statistical significance. Notably, the prognosis of","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 3","pages":"682-690"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical Features, Prognostic Analysis and Predictive Model Construction of Central Nervous System Invasion in Peripheral T-Cell Lymphoma].","authors":"Ya-Ting Ma, Yan-Fang Chen, Zhi-Yuan Zhou, Lei Zhang, Xin Li, Xin-Hua Wang, Xiao-Rui Fu, Zhen-Chang Sun, Yu Chang, Fei-Fei Nan, Ling Li, Ming-Zhi Zhang","doi":"10.19746/j.cnki.issn.1009-2137.2025.03.020","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.03.020","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the clinical features and prognosis of central nervous system (CNS) invasion in peripheral T-cell lymphoma (PTCL) and construct a risk prediction model for CNS invasion.</p><p><strong>Methods: </strong>Clinical data of 395 patients with PTCL diagnosed and treated in the First Affiliated Hospital of Zhengzhou University from 1st January 2013 to 31st December 2022 were analyzed retrospectively.</p><p><strong>Results: </strong>The median follow-up time of 395 PTCL patients was 24(1-143) months. There were 13 patients diagnosed CNS invasion, and the incidence was 3.3%. The risk of CNS invasion varied according to pathological subtype. The incidence of CNS invasion in patients with anaplastic large cell lymphoma (ALCL) was significantly higher than in patients with angioimmunoblastic T-cell lymphoma (AITL) (<i>P</i> <0.05). The median overall survival was significantly shorter in patients with CNS invasion than in those without CNS involvement, with a median survival time of 2.4(0.6-127) months after diagnosis of CNS invasion. The results of univariate and multivariate analysis showed that more than 1 extranodal involvement (<i>HR</i>=4.486, 95%<i>CI</i> : 1.166-17.264, <i>P</i> =0.029), ALCL subtype (<i>HR</i>=9.022, 95%<i>CI</i> : 2.289-35.557, <i>P</i> =0.002) and ECOG PS >1 (<i>HR</i>=15.890, 95%<i>CI</i> : 4.409-57.262, <i>P</i> <0.001) were independent risk factors for CNS invasion in PTCL patients. Each of these risk factors was assigned a value of 1 point and a new prediction model was constructed. It could stratify the patients into three distinct groups: low-risk group (0-1 point), intermediate-risk group (2 points) and high-risk group (3 points). The 1-year cumulative incidence of CNS invasion in the high-risk group was as high as 50.0%. Further evaluation of the model showed good discrimination and accuracy, and the consistency index was 0.913 (95%<i>CI</i> : 0.843-0.984).</p><p><strong>Conclusion: </strong>The new model shows a precise risk assessment for CNS invasion prediction, while its specificity and sensitivity need further data validation.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 3","pages":"760-768"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Curative Efficacy Analysis of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia with <i>ASXL1</i> Mutation].","authors":"Ya-Jie Shi, Xin-Sheng Xie, Zhong-Xing Jiang, Ding-Ming Wan, Rong Guo, Tao Li, Xia Zhang, Xue Li, Yu-Pei Zhang, Yue Su","doi":"10.19746/j.cnki.issn.1009-2137.2025.03.014","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.03.014","url":null,"abstract":"<p><strong>Objective: </strong>To explore the efficacy and apoptosis of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of acute myeloid leukemia (AML) with <i>ASXL1</i> mutation.</p><p><strong>Methods: </strong>The clinical data of 80 AML patients with <i>ASXL1</i> mutation treated in our hospital from January 2019 to December 2021 were retrospectively analyzed. The clinical characteristics of the patients were summarized, and the therapeutic effect and prognostic factors of allo-HSCT for the patients were analyzed.</p><p><strong>Results: </strong>Among the 80 patients, 38 were males and 42 were females, and the median age was 39(14-65) years. There were 17 patients in low-risk group, 25 patients in medium-risk group and 38 patients in high-risk group. <i>ASXL1</i> mutation co-occurred with many other gene mutations, and the frequent mutated genes were <i>TET2</i> (71.25%), <i>NRAS</i> (18.75%), <i>DNMT3A</i> (16.25%), <i>NPM1</i> (15.00%), <i>CEBPA</i> (13.75%). Among medium and high-risk patients, 29 underwent allo-HSCT, while 34 received chemotherapy. The 2-year overall survival (OS) rate and disease-free survival (DFS) rate of the allo-HSCT group were 72.4% and 70.2%, while those of the chemotherapy group were 44.1% and 34.0%, respectively. The statistical analysis showed significant differences between the two groups (both <i>P</i> < 0.01). Multivariate analysis showed that age at transplantation >50- years and occurrence of acute graft-versus-host disease after transplantation were poor prognostic factors for OS and DFS in transplantation patients.</p><p><strong>Conclusion: </strong>Allo-HSCT can improve the prognosis of AML patients with <i>ASXL1</i> mutation.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 3","pages":"720-725"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Effects of Bortezomib Combined with Polyphyllin Ⅶ on Proliferation, Apoptosis and Oxidative Stress of Myeloma Cells].","authors":"Ou-Xiao Ji, Yao Fu, Yu-Qing Sun, Li-Juan Wang","doi":"10.19746/j.cnki.issn.1009-2137.2025.03.026","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.03.026","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effects of bortezomib (BTZ) combined with polyphyllin Ⅶ (PP7) on proliferation, apoptosis and oxidative stress of myeloma cell line ARH-77.</p><p><strong>Methods: </strong>MTT assay was used to detect the inhibitory effects of different concentrations of BTZ, PP7 monotherapy, and their combination on the proliferation of ARH-77 cells. In subsequent experiments, the cells were divided into 4 groups: control group (no drug added), BTZ (15 nmol/L) group, PP7 (1.5 μmol/L) group and BTZ(15 nmol/L)+PP7 (1.5 μmol/L) group. The effects of the two drugs on the morphology of ARH-77 cells were observed. Flow cytometry was used to detect the apoptosis rate of the cells in each group. Calcein-AM/PI double staining kit was used to observe the status of the cells and the cell viability were evaluated. The expression of apoptosis-related proteins were detected by Western blot. DCFH-DA fluorescent probe was used to detect the levels of reactive oxygen species (ROS).</p><p><strong>Results: </strong>Both BTZ and PP7 monotherapy, as well as their combination, could inhibit the growth of ARH-77 cells in a dose-dependent manner (r_BTZ=-0.9717, r_PP7=-0.9941, r_BTZ+PP7=-0.9951), and the combination of BTZ and PP7 exhibited a synergistic effect within a certain concentration range. Compared with the BTZ group and PP7 group, the apoptosis rate of the BTZ+PP7 group was significantly increased (<i>P</i> < 0.01), the expressions of pro-apoptotic proteins Bax, Smac and P53 were significantly upregulated (<i>P</i> < 0.05), the expression of anti-apoptotic protein Bcl-2 was significantly downregulated (<i>P</i> < 0.01), and the ratio of Bax/Bcl-2 was significantly increased (<i>P</i> < 0.01). Compared with the control group, the level of ROS in the BTZ, PP7 monotherapy group and BTZ+PP7 group were significantly increased (<i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>BTZ combined with PP7 can inhibit the proliferation and induce apoptosis of ARH-77 cells, and increase the level of intracellular ROS.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 3","pages":"802-809"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Knocking Out <i>DNMT1</i> Enhances the Inhibitory Effect of NK Cells on Acute Myeloid Leukemia].","authors":"Kun Wu, Jia-Li Huang, Shen-Ju Cheng, Yan-Hong Li, Yun Zeng, Ming-Xia Shi","doi":"10.19746/j.cnki.issn.1009-2137.2025.03.005","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.03.005","url":null,"abstract":"<p><strong>Objective: </strong>To explore the effect and mechanism of DNA methyltransferase 1 (DNMT1) knockout on the inhibition of acute myeloid leukemia (AML) by natural killer (NK) cells.</p><p><strong>Methods: </strong>The peripheral blood NK cells of AML patients and controls were collected, and the mRNA and protein level of DNMT1 were measured by PCR and Western blot, respectively. The <i>DNMT1</i> knockout mice were constructed to obtain NK^DNMT1-/- cells. The NK cells were stimulated with interleukin (IL)-12, IL-15, and IL-18 to construct memory NK cells, and then the interferon-γ (IFN-γ) levels were measured by ELISA. After co-culturing with memory NK cells and HL60 cells, the killing effect of NK^DNMT1-/- cells on HL60 cells was detected by LDH assay. Then, the HL60 cell apoptosis and NK cell NKG2D level were measured by flow cytometry. The perforin and granzyme B protein levels of NK cells were measured by Western blot. The AML model mice were constructed by injecting HL60 cells into the tail vein, meanwhile, memory NK cells were also injected, and then the mouse weights, CD33 positive rates, and survival time were detected.</p><p><strong>Results: </strong>The mRNA and protein levels of DNMT1 in NK cells of AML patients were significantly higher than those in the control group (both <i>P</i> < 0.01), while the IFN-γ level induced by interleukin was significantly lower than that in the control group (<i>P</i> < 0.05). Compared with NK^DNMT1+/+ cells, the ability of NK^DNMT1-/- cells to secrete IFN-γ after interleukin stimulation was significantly increased (<i>P</i> < 0.05). The killing and apoptosis-inducing effects of NK^DNMT1-/- cells on HL60 cells were significantly stronger than those of NK^DNMT1+/+ cells (both <i>P</i> < 0.05). The NKG2D level and expression of perforin and granzyme B of NK^DNMT1-/- cells were significantly increased compared with NK^DNMT1+/+ cells (all <i>P</i> < 0.05). Compared with AML mice injected with NK^DNMT1+/+ cells, AML mice injected with NK^DNMT1-/- cells showed significantly increased body weight, decreased CD33 positive rate, and prolonged survival time (all <i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>Knocking out <i>DNMT1</i> can enhance the inhibitory effect of NK cells on AML, which may be related to enhancing NK cell memory function.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 3","pages":"653-659"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}